The European Society for Medical Oncology (ESMO) holds its annual primary meeting to provide an opportunity for researchers from across the world to come together to discuss the latest, exciting advances in cancer treatment. This year, ESMO took place in Madrid, Spain from October 23 to October 27, 2026. ESMO 2026 brought three promising updates in endometrial cancer.
See below for a guide to the news you should know from ESMO 2026:
1. Experimental drug improves outcomes after previous treatment, now under FDA priority review
In the phase 3 TroFuse-005 trial, the experimental drug sacituzumab tirumotecan (sac-TMT) helped people with advanced or recurrent endometrial cancer live longer after their cancer had progressed after platinum-based chemotherapy and immunotherapy. Patients receiving sac-TMT lived a median of 19 months, compared with 12.1 months for those receiving other chemotherapy options, and went an average of 7.2 months before their cancer worsened, compared with 3.9 months. Tumors shrank in about 35% of patients receiving sac-TMT, compared with 17% receiving other chemotherapy. The drug is designed to deliver cancer-killing medicine directly to cancer cells by targeting a protein called TROP2.
These results offer hope for people whose cancer has returned or continued growing after standard treatments, a group with limited options. The FDA has accepted the drug for priority review.
2. Pembrolizumab alone delays cancer growth in certain patients
The phase 3 KEYNOTE-C93 trial found that pembrolizumab (Keytruda), an immunotherapy drug, delayed cancer growth longer than standard chemotherapy in people with advanced or recurrent endometrial cancer whose tumors have a feature called mismatch repair deficiency (dMMR). Patients receiving pembrolizumab went a median of 38.2 months before their cancer worsened, compared with 8.4 months for those receiving chemotherapy. Serious treatment-related side effects were also less common with pembrolizumab than with chemotherapy, occurring in 18.1% of patients versus 50.7%.
These findings suggest that some patients may be able to start treatment with immunotherapy alone rather than chemotherapy, potentially avoiding some chemotherapy-related side effects while keeping cancer under control longer. Tumor testing is essential to determine whether this approach may be appropriate, and further follow-up is needed to clarify its effect on survival.
3. Immunotherapy combination helps people with advanced or recurrent endometrial cancer live longer
The phase 3 DUO-E trial found that people with advanced or recurrent endometrial cancer who received durvalumab (Imfinzi) with chemotherapy, followed by durvalumab and olaparib (Lynparza), lived a median of 51.1 months, compared with 39.6 months for those who received chemotherapy alone. This represents an improvement of nearly one year in median overall survival, meaning the time patients lived after entering the study. The combination was especially encouraging for people whose tumors were mismatch repair proficient (pMMR), a common tumor type that has historically had fewer effective treatment options.
These results suggest that this immunotherapy treatment combination may help people live longer, including those whose tumors have fewer treatment options. Researchers will continue following patients to better understand the long-term benefits.
Disclaimer: The information provided in this article is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Outcomes4Me is not acting as your caregiver, and any suggestions or guidance offered should not replace the advice of your healthcare provider or qualified medical professional. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition.